Summary
Plasma concentrations and bioavailability of disopyramide following repeated administration of standard capsules and controlled-release tablets have been compared. Ten patients were randomized into two groups; Group I received disopyramide capsules 150 mg every 6 h for five days and subsequently disopyramide controlled-release tablets 300 mg every 12 h for further five days. Group II received the same preparations in the reverse order. There was a more rapid rise in disopyramide concentration after the capsules: the maximum of 10.7±0.6 µmol/l (mean ± SEM) was reached within 1.8±0.4 h as compared to 10.6±0.4 µmol/l within 4.0±0.3 h after the controlled-release tablets. No significant difference in the fluctuations in individual plasma concentrations during each dose interval at steady state were observed after ordinary capsules compared to controlled-release tablets. The extent of bioavailability was the same. Eight patients reported some side-effects during the capsule period and nine during the controlled-release tablet period.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baines MW, Davies JE, Kellett DN, Munt PL (1976) Some pharmacological effects of disopyramide and a metabolite. J Int Med Res 4: Suppl (1), 5–7
Dreifus LS, Filip Z, Sexton DM (1973) Electrophysiological and clinical effects of a new antiarrhythmic agent: Disopyramide. Am J Cardiol 31: 129–136
Graffner C, Lagerström PO, Lundborg P (1980) Relative absorption of disopyramide following acute administration of standard capsules and controlled-release tablets determinded by liquid chromatography. J. Pharm. Pharmacol (Submitted for publication)
Hinderling PH, Garrett ER (1976) Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans. J Pharmacokinet Biopharm 4: 199–230
Hulting J, Jansson B (1977) Antiarrhythmic and electrocardiographic effects of single oral doses of disopyramide. Eur J Clin Pharmacol 11: 91–99
Johansson R, Regårdh CG, Sjögren J (1971) Absorption of alprenolol in man from tablets with different rates of release. Acta Pharm Suec 8: 59–70
Karim A (1975) The pharmacokinetics of Norpace. Norpace Seminar. Angiology Suppl (1) part 2, 26: 85–98
Lagerström PO, Persson B-A (1978) Liquid chromatography in the monitoring of plasma levels of antiarrhythmic drugs. J Chromatogr 149: 331–340
Meffin PJ, Robert EW, Winkle RA, Harapat S, Peters FA, Harrison DC (1979) Role of concentration-dependent plasma protein binding in disopyramide disposition. J Pharmacokinet Biopharm 7: 29–46
Niarchos AP (1976) Disopyramide: Serum level and arrhythmia conversion. Am Heart J 92: 57–64
Oshrain C, Arif M, Cook WR, Laidlaw JC, Willis PW (1976) A double blind comparison of disopyramide phosphate and quinidine sulphate as antiarrhythmic agents. Report from Scientific Exhibit. 40th Scientific Sessions, American Heart Association, Miami, Florida
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Forssell, G., Graffner, C., Nordlander, R. et al. Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets. Eur J Clin Pharmacol 17, 209–213 (1980). https://doi.org/10.1007/BF00561902
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561902